The BAFF inhibitor, belimumab, has been approved for the treatment of system lupus erythematosus patients characterized by IgG overproduction and eLT formation, and exhibits modest, but durable, efficacy in decreasing disease flares and organ damage (48, 49). The gene discussed is TNFSF13B; the disease is lupus erythematosus.